NEUROBO PHARMACEUTICALS INC (NRBO) Fundamental Analysis & Valuation

NASDAQ:NRBO • US64132R4048

Current stock price

2.36 USD
+0.01 (+0.43%)
Last:

This NRBO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NRBO Profitability Analysis

1.1 Basic Checks

  • In the past year NRBO has reported negative net income.
  • NRBO had a negative operating cash flow in the past year.
  • NRBO had negative earnings in each of the past 5 years.
  • In the past 5 years NRBO always reported negative operating cash flow.
NRBO Yearly Net Income VS EBIT VS OCF VS FCFNRBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • NRBO has a worse Return On Assets (-125.23%) than 80.60% of its industry peers.
  • The Return On Equity of NRBO (-214.10%) is worse than 68.78% of its industry peers.
Industry RankSector Rank
ROA -125.23%
ROE -214.1%
ROIC N/A
ROA(3y)-62.45%
ROA(5y)-121.04%
ROE(3y)-81.21%
ROE(5y)-165.85%
ROIC(3y)N/A
ROIC(5y)N/A
NRBO Yearly ROA, ROE, ROICNRBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NRBO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRBO Yearly Profit, Operating, Gross MarginsNRBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NRBO Health Analysis

2.1 Basic Checks

  • NRBO has less shares outstanding than it did 1 year ago.
  • There is no outstanding debt for NRBO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NRBO Yearly Shares OutstandingNRBO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
NRBO Yearly Total Debt VS Total AssetsNRBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -10.54, we must say that NRBO is in the distress zone and has some risk of bankruptcy.
  • NRBO's Altman-Z score of -10.54 is on the low side compared to the rest of the industry. NRBO is outperformed by 75.31% of its industry peers.
  • NRBO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.54
ROIC/WACCN/A
WACCN/A
NRBO Yearly LT Debt VS Equity VS FCFNRBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 2.41 indicates that NRBO has no problem at all paying its short term obligations.
  • NRBO's Current ratio of 2.41 is on the low side compared to the rest of the industry. NRBO is outperformed by 71.43% of its industry peers.
  • A Quick Ratio of 2.41 indicates that NRBO has no problem at all paying its short term obligations.
  • NRBO has a worse Quick ratio (2.41) than 70.19% of its industry peers.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.41
NRBO Yearly Current Assets VS Current LiabilitesNRBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NRBO Growth Analysis

3.1 Past

  • NRBO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.98%, which is quite impressive.
EPS 1Y (TTM)62.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 17.81% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.04%
EPS Next 2Y26.29%
EPS Next 3Y17.81%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRBO Yearly EPS VS EstimatesNRBO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K -2.5K

More info and screens

Find the best growth stocksShow best growing peers

0

4. NRBO Valuation Analysis

4.1 Price/Earnings Ratio

  • NRBO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NRBO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRBO Price Earnings VS Forward Price EarningsNRBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRBO Per share dataNRBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • NRBO's earnings are expected to grow with 17.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.29%
EPS Next 3Y17.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NRBO Dividend Analysis

5.1 Amount

  • NRBO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NRBO Fundamentals: All Metrics, Ratios and Statistics

NEUROBO PHARMACEUTICALS INC

NASDAQ:NRBO (11/27/2024, 8:56:43 PM)

2.36

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)N/A
Inst Owners12.52%
Inst Owner Change0%
Ins Owners75.88%
Ins Owner Change0%
Market Cap20.34M
Revenue(TTM)N/A
Net Income(TTM)-27.73M
Analysts85
Price Target27.2 (1052.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.66%
Min EPS beat(2)-61.46%
Max EPS beat(2)26.13%
EPS beat(4)2
Avg EPS beat(4)-38.93%
Min EPS beat(4)-184.75%
Max EPS beat(4)64.34%
EPS beat(8)5
Avg EPS beat(8)-2.17%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)27%
EPS NQ rev (3m)26.04%
EPS NY rev (1m)8.67%
EPS NY rev (3m)8.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB 1.57
EV/EBITDA N/A
EPS(TTM)-6
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS0
BVpS1.5
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -125.23%
ROE -214.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.45%
ROA(5y)-121.04%
ROE(3y)-81.21%
ROE(5y)-165.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.41
Altman-Z -10.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)277.78%
Cap/Depr(5y)376.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.61%
EPS Next Y-4.04%
EPS Next 2Y26.29%
EPS Next 3Y17.81%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-132.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-77.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-77.12%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROBO PHARMACEUTICALS INC / NRBO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NEUROBO PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 2 / 10 to NRBO.


What is the valuation status of NEUROBO PHARMACEUTICALS INC (NRBO) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROBO PHARMACEUTICALS INC (NRBO). This can be considered as Overvalued.


Can you provide the profitability details for NEUROBO PHARMACEUTICALS INC?

NEUROBO PHARMACEUTICALS INC (NRBO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for NRBO stock?

The Earnings per Share (EPS) of NEUROBO PHARMACEUTICALS INC (NRBO) is expected to decline by -4.04% in the next year.